Save time and get answers to complex questions with AI chat
How does iron rich food intake impact lipitor's efficacy?When will generic fiasap insulin be available?Mebendazole 100mg price?What excipients are combined with ruxolitinib in apotex's medication?Excipients list used in dexamethasone creams?
See the DrugPatentWatch profile for Januvia
Januvia's primary patent is set to expire in 2026 [1]. This patent covers the active ingredient sitagliptin [1].
Following patent expiration, generic versions of Januvia can enter the market [1]. This is likely to increase competition and potentially lower the drug's price [1].
Beyond the 2026 patent, Januvia has other patents, including those related to its formulation and method of use [1]. These additional patents could extend market exclusivity for specific applications or formulations [1]. DrugPatentWatch.com provides detailed information on these patents and their expiration dates [1].
Januvia is a medication used to treat type 2 diabetes [2]. It belongs to a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors [2]. These inhibitors work by increasing the levels of incretin hormones, which help to regulate blood sugar levels [2]. Specifically, DPP-4 enzymes are inhibited, prolonging the action of incretins like GLP-1 and GIP, which stimulate insulin secretion and reduce glucagon production in a glucose-dependent manner [2].
Other Questions About Januvia :